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Abstract Tigecycline, a broad-spectrum antibiotic for
parenteral use, was introduced in Germany in May 2006.
In the G-TEST-II trial, the susceptibility of isolates,
recovered in 2007 from hospitalised patients in 15 centres,
was assessed against tigecycline and comparators. Suscep-
tibility tests were performed by the microdilution proce-
dure. This study reports on the susceptibility of the isolates
of 16 bacterial species and compares the results with those
of a trial (G-TEST I) conducted prior to the introduction of
tigecycline. Between 2005 and 2007, tigecycline retained
activity against Gram-positive and Gram-negative organisms.
By contrast, the rate of vancomycin-resistant strains among
Enterococcus faecium isolates almost doubled. Moreover, an
increase in resistance to broad-spectrum beta-lactams and
fluoroquinolones was observed for members of the family
Enterobacteriaceae. Against a background of a steadily
rising number of pathogens that are resistant to various
antibiotic classes, tigecycline represents an important treat-
ment option.
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48159 Münster, GermanyTigecycline (Tygacil®), the first glycylcycline with in-vitro
activityagainstmanyaerobicandanaerobicGram-positiveand
Gram-negative organisms [1], was introduced in Germany in
May 2006. The drug, which is administered intravenously, is
indicated for complicated skin and skin structure infections
and complicated intra-abdominal infections. The recommen-
ded standard dosage is 100 mg as a loading dose, followed by
50 mg every 12 h over a period of 5 to 14 days. In a second
Tigecycline Evaluation Surveillance Trial conducted through-
out Germany (G-TEST II), the susceptibility of over 2,400
bacterial isolates, collected one year after the introduction of
the new compound, was tested against tigecycline and
comparators. This study reports on the susceptibility of the
isolates of 16 bacterial species and compares the results with
those of a trial performed one year prior to the introduction of
tigecycline (2005) (G-TEST I) [2].
The same 15 medical microbiology laboratories that had
participated in G-TEST I cooperated in this trial. In
accordance with the study protocol, in the period from May
to September 2007, each laboratory was asked to include in
the study a maximum of 200 isolates recovered from
hospitalised patients with community-acquired or nosocomial
infections. Data from the following bacterial species and
groups were evaluated: Enterococcus faecalis, E. faecium,
oxacillin (methicillin)-susceptible Staphylococcus aureus
(MSSA), oxacillin (methicillin)-resistant S. aureus (MRSA),
S. haemolyticus, S. epidermidis, Streptococcus agalactiae, S.
pneumoniae, S. pyogenes, Acinetobacter baumannii group,
Escherichia coli, Enterobacter cloacae, Haemophilus influ-
enzae, Klebsiella oxytoca, K. pneumoniae, Serratia marces-
cens and Stenotrophomonas maltophilia.
Only first isolates from the following sources were
accepted for inclusion: peritoneal cavity, respiratory tract,
blood, wounds and urine (<10% of the isolates). Coagulase-
negative staphylococci were only included in the study if they
were recovered from at least two consecutive blood samples.
Identification of the pathogens was performed using
standard laboratory methods. The bacterial strains were
then conserved at −70°C and sent to a central laboratory
(Antiinfectives Intelligence) for susceptibility testing at the
end of the collection period.
Minimal inhibitory concentrations (MICs) were deter-
mined using the microdilution broth method according to
the standard ISO 20776-1:2006 [3]. The test medium was
Mueller-Hinton II broth (Becton Dickinson GmbH, Heidel-
berg). Testing of the streptococci was performed using 3%
lysed horse blood (Oxoid GmbH, Wesel). Haemophilus test
medium was used to determine the susceptibility of H.
influenzae. The following reference strains were included as
quality controls: E. faecalis ATCC 29212, E. coli ATCC
25922, H. influenzae ATCC 49247, P. aeruginosa ATCC
27853, S. aureus ATCC 29213, S. aureus ATCC 43300 and
S. pneumoniae ATCC 49619.
Susceptibility to the following antibacterial agents was
tested: Gram-positive bacteria – amoxicillin-clavulanic
acid, cefuroxime, doxycycline, gentamicin, imipenem, line-
zolid, moxifloxacin, oxacillin, penicillin G, piperacillin-
tazobactam, tigecycline and vancomycin; Gram-negative
bacteria–amoxicillin-clavulanicacid, cefepime, cefotaxime,
ceftazidime, ciprofloxacin, doxycycline, ertapenem, genta-
micin, imipenem, moxifloxacin, piperacillin-tazobactam and
tigecycline.
In order to categorise the bacteria as susceptible,
intermediate or resistant, the species-related breakpoints
approved by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) were used, if available
[4, 5]. The MICs of doxycycline for Enterobacteriaceae
and enterococci were interpreted by the cut-off values given
by the German standard DIN 58940 [6].
Isolates of E. coli and Klebsiella spp. were tested for
extended-spectrum beta-lactamase (ESBL) production
according to the broth dilution procedure described by the
Clinical Laboratory Standards Institute (CLSI) [7].
A total of 2,420 bacterial strains were included in the
study. The majority of isolates were cultured from
respiratory tract specimens (34%), wound swabs (29%),
blood (21%) and intra-abdominal material (8%). Sixty-eight
percent of the isolates came from patients on general wards
and 32% from patients in intensive care units. More than
60% of the patients were male. The age of the patients
ranged from <1 to 107 years (median: 63 years).
Each reference strain was included at least five times in
the susceptibility testing. With one exception, MICs fell
into tolerance ranges (as far as available). The MICs of
imipenem for E. coli ATCC 25922 were, in part, above the
upper breakpoint of the tolerance range.
Table 1 shows the resistance rates of 15 organisms for
selected antibacterial agents, as well as changes compared
to the 2005 trial (G-TEST I), while Tables 2 and 3 of the
supplementary material present comprehensive results of
both trials, including the MIC50 and MIC90 values and the
susceptibility and resistance rates of all of the tested drugs
for the 16 bacterial species.
Gram-positive bacteria
Compared with the situation prior to its introduction,
tigecycline demonstrated unchanged high in-vitro activity
against Gram-positive organisms. With the exception of
three S. haemolyticus isolates, all Gram-positive bacteria
tested were categorised as tigecycline-susceptible.
The MIC90 values of tigecycline for MSSA, MRSA, S.
epidermidis and S. haemolyticus ranged between
≤0.125 μg/mL and 0.5 μg/mL. The MIC values of the S.
haemolyticus isolates categorised as resistant were each one
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(G-TEST I)
Organism (n) Antibacterial agent % R % Δ Organism (n) Antibacterial agent % R % Δ
E. faecalis (149) Tigecycline 0 0 A. baumannii group
(117)
Tigecycline n.d. –
Doxycycline 59.7 −11.0 Imipenem 11.1 +10.4
Amoxicillin-clavulanic
acid
0.7 +0.7 Ciprofloxacin 27.4 −2.6
Linezolid 0 0 Gentamicin 22.2 +8.6
Vancomycin 0 0 E. cloacae (223) Tigecycline 6.3 −0.6
Gentamicin (high
level)
a
38.9 +0.9 Doxycycline 10.8 0
E. faecium (142) Tigecycline 0 0 Piperacillin-tazobactam 22.0 +3.5
Doxycycline 6.3 −5.4 Cefotaxime 42.6 +2.1
Amoxicillin-clavulanic
acid
93.0 +1.3 Ceftazidime 34.1 +4.8
Linezolid 0 −0.7 Cefepime 2.2 −1.2
Vancomycin 18.3 +8.6 Imipenem 0 0
Gentamicin (high
level)
a
37.3 −6.1 Ciprofloxacin 7.2 +1.6
Oxacillin-susceptible S. aureus
(153)
Tigecycline 0 0 Gentamicin 6.3 +1.6
Doxycycline 2.6 −0.8 E. coli (292) Tigecycline 0 0
Moxifloxacin 11.8 −1.7 Doxycycline 40.4 −3.6
Linezolid 0 0 Amoxicillin-clavulanic
acid
28.8 +4.5
Vancomycin 0 0 Piperacillin-tazobactam 6.2 +2.5
Gentamicin 7.8 −0.4 Cefotaxime 12.3 +7.0
Oxacillin-resistant S. aureus
(155)
Tigecycline 0 0 Ceftazidime 5.8 +3.8
Doxycycline 3.9 −1.9 Cefepime 9.9 +6.9
Moxifloxacin 94.8 +3.9 Imipenem 0 0
Linezolid 0 0 Ciprofloxacin 28.4 +6.7
Vancomycin 0 0 Gentamicin 10.3 +2.6
Gentamicin 12.9 −9.8 H. influenzae (225) Tigecycline n.d. –
S. epidermidis (142) Oxacillin 83.1 −0.4 Doxycycline 0.9 +0.9
Tigecycline 0 0 Amoxicillin-clavulanic
acid
5.3 +2.1
Doxycycline 9.2 −0.9 Ciprofloxacin 0 0
Moxifloxacin 52.1 +9.8 K. oxytoca (109) Tigecycline 1.8 −0.2
Linezolid 0 0 Doxycycline 16.5 +12.5
Vancomycin 0 0 Amoxicillin-clavulanic
acid
25.7 +10.7
Gentamicin 56.3 −9.2 Piperacillin-tazobactam 23.9 +9.9
S. haemolyticus (66) Oxacillin 90.9 +0.5 Cefotaxime 15.6 +12.6
Tigecycline 4.5 +3.1 Ceftazidime 0.9 +0.9
Doxycycline 12.1 +6.6 Cefepime 2.8 +2.8
Moxifloxacin 51.5 −6.0 Imipenem 0 0
Linezolid 0 0 Ciprofloxacin 13.8 +7.8
Vancomycin 0 0 Gentamicin 4.6 +3.6
Gentamicin 84.8 +4.0 K. pneumoniae (185) Tigecycline 7.0 −5.4
S. agalactiae (76) Tigecycline 0 0 Doxycycline 26.5 −0.4
Doxycycline 77.6 +6.9 Amoxicillin-clavulanic
acid
19.5 +6.1
Penicillin G 0 0 Piperacillin-tazobactam 10.3 +2.2
Moxifloxacin 0 0 Cefotaxime 13.5 +8.1
Linezolid 0 0 Ceftazidime 10.3 +6.0
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isolates with susceptibility to doxycycline was approxi-
mately 95% each for MSSA und MRSA and approximately
85% each for the two coagulase-negative species. Among
MRSA isolates, the proportion of gentamicin-resistant
strains, at 12.9%, was less in this study than in G-TEST I.
A negative trend for gentamicin resistance was also
observed for S. epidermidis, although at a markedly higher
level. Staphylococci with reduced susceptibility to vanco-
mycin or linezolid were not detected.
The proportion of vancomycin-resistant enterococci
(VRE) among the E. faecium isolates was 18.3% in this
study, almost twice as high as in G-TEST I (9.7%), whereas
the isolates of E. faecalis were 100% susceptible to
vancomycin. No linezolid-resistant enterococci were
detected. Tigecycline showed unchanged high in-vitro
activity against both enterococcal species (including VRE)
with MIC90 values of ≤0.125 μg/mL. The proportion of
doxycycline-resistant strains in this trial was less than in G-
TEST I. The resistance rate in E. faecalis was, however,
still approximately 60%.
Tigecycline again showed high in-vitro activity
against the three streptococcal species investigated
(MIC90 of ≤0.125 μg/mL in each case). By contrast, the
proportion of doxycycline-resistant isolates was 11.4% for
S. pneumoniae,1 7 . 5 %f o rS. pyogenes and 77.6% for
S. agalactiae.
Gram-negative bacteria
Of the E. coli isolates, 99.3% were tigecycline-susceptible,
while more than 40% were categorised as doxycycline-
resistant. The MIC values of tigecycline for two doxycycline-
resistant isolates were in the intermediate range (2 μg/mL). The
proportion of E. coli isolates with resistance to ciprofloxacin
rose between 2005 and 2007 from 21.7% to over 28.4%. The
increase of resistance to cefotaxime correlated with a rise of
ESBL-producing strains, from 5.3% to 12.3%.
The activity of tigecycline against E. cloacae, K.
pneumoniae, K. oxytoca and S. marcescens was comparable
in both studies. By contrast, the proportion of isolates
classified as ESBL-producers increased from 9% to 17.4%
for K. oxytoca and from 4.3% to 14.6% for K. pneumoniae.
Concurrently, a marked increase in resistance to fluoroqui-
nolones was detected in both species. In the case of K.
oxytoca,t h e r ew a sa l s oa ni n c r e a s ei nr e s i s t a n c et o
doxycycline and piperacillin-tazobactam, and for S. mar-
cescens, an increase in resistance to fluoroquinolones,
cefotaxime and piperacillin-tazobactam was observed.
As in G-TEST I, tigecycline again showed high activity
against isolates of the A. baumannii group. The MIC50/90
values (0.25/1 μg/mL) were comparable with the values
obtained in G-TEST I (0.25/0.5 μg/mL). By contrast, the
percentage of isolates with resistance to imipenem was
11.1% in this trial, compared with <1% in G-TEST I.
Table 1 (continued)
Organism (n) Antibacterial agent % R % Δ Organism (n) Antibacterial agent % R % Δ
Vancomycin 0 0 Cefepime 7.6 +2.8
S. pneumoniae (70) Tigecycline n.d. – Imipenem 0 0
Doxycycline 11.4 +6.2 Ciprofloxacin 16.8 +8.7
Penicillin G 0 0 Gentamicin 5.4 +2.2
Moxifloxacin 0 0 S. marcescens (124) Tigecycline 2.4 −1.0
Linezolid 0 0 Doxycycline 42.7 +1.2
Vancomycin 0 0 Piperacillin-tazobactam 9.7 +7.2
S. pyogenes (63) Tigecycline 0 0 Cefotaxime 17.7 +10.9
Doxycycline 17.5 +4.5 Ceftazidime 1.6 −0.1
Penicillin G 0 0 Cefepime 0 −2.5
Moxifloxacin 0 0 Imipenem 0 0
Linezolid 0 0 Ciprofloxacin 12.9 +7.0
Vancomycin 0 0 Gentamicin 2.4 −0.1
% R = % resistant; % Δ = percentage changes compared to the 2005 trial (G-TEST I)
n.d. = not determined, as no species-related breakpoint has been approved by the EUCAST. All isolates of S. pneumoniae, A. baumannii group
and H. influenzae were inhibited at <0.125, 4 and 0.5 mg tigecycline per mL, respectively
aMIC > 500 mg/l
1010 Eur J Clin Microbiol Infect Dis (2009) 28:1007–1011Based on the MIC50/90 values, no changes in the
antimicrobial susceptibility of S. maltophilia isolates were
observed. In both trials, the lowest MIC90 values were
determined for tigecycline (1–2 μg/mL) and moxifloxacin
(2 μg/mL).
Comparison of the results of the present trial with those
of G-TEST I shows no significant changes in the
susceptibility to tigecycline of the species tested [2]. By
contrast, the frequency of resistance of E. coli to fluo-
roquinolones increased considerably and was over 28% in
this trial. This value corresponds well to the rate of
ciprofloxacin resistance from a study recently performed
by the Paul-Ehrlich-Society (PEG) in Germany [8]. The
latest rate of ciprofloxacin resistance for German blood
culture isolates published by the European Antimicrobial
Resistance Surveillance System (EARSS) was 30% [9]. Of
concern is the marked rise in cefotaxime resistance due to
the spread of ESBL-producing isolates in E. coli and other
Enterobacteriaceae species. Compared with the trial con-
ducted in 2005, the increase in the prevalence of ESBL-
producers observed for E. coli (from approximately 5% to
over 12%) and K. pneumoniae (from 4.3% to almost 15%)
also corresponds with the results of a resistance study
performed by the PEG [8].
Overall, tigecycline remained universally active against
E. coli, E. cloacae, K. pneumoniae, S. maltophilia and
against isolates of the A. baumannii group.
No statement can be made about the prevalence of
MRSA due to the specific study design. For tigecycline,
there was no change in activity against staphylococci,
enterococci and streptococci, including MRSA, VRE and
doxycycline-resistant strains. However, tigecycline resis-
tance has been described for E. faecalis and S. aureus [10,
11]. In two tigecycline-resistant laboratory mutants of S.
aureus (MICs 4–16 μg/mL), obtained following serial
passage in increasing concentrations of this drug, the
overexpression of a novel MATE efflux pump (MepA)
was shown to contribute to the reduced susceptibility [10],
whereas the resistance mechanism in one tigecycline-
resistant clinical isolate of E. faecalis (MIC 1 μg/mL) has
not yet been elucidated [11].
In summary, one year after the introduction of tigecy-
cline, it can be ascertained that no change in the resistance
situation has yet been observed for any of the bacterial
species tested. Against a background of a steadily rising
number of pathogens that are resistant to various antibiotic
classes, tigecycline represents an important treatment
option.
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